Amphotericin B ocular films for fungal keratitis and a novel 3D printed microfluidic ocular lens infection model

Tools

Rapti, Chrysi and Luciano, Francis C. and Anaya, Bryan J. and Ramirez, Bianca I. and Ongoren, Baris and Dea-Ayuela, María Auxiliadora and Lalatsa, Aikaterini and Serrano, Dolores R. (2024) Amphotericin B ocular films for fungal keratitis and a novel 3D printed microfluidic ocular lens infection model. Journal of Fungi, 10 (11). 762. ISSN 2309-608X (https://doi.org/10.3390/jof10110762)

[thumbnail of Rapti-etal-JF-2024-Amphotericin-B-ocular-films-for-fungal-keratitis]
Preview
 Text. Filename: Rapti-etal-JF-2024-Amphotericin-B-ocular-films-for-fungal-keratitis.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (2MB)| Preview

Abstract

Fungal keratitis (FK), a severe eye infection that leads to vision impairment and blindness, poses a high risk to contact lens users, and Candida albicans remains the most common underpinning fungal pathogen in temperate climates. Patients are initially treated empirically (econazole 1% drops hourly for 24–48 h), and if there is no response, amphotericin B (AmB) 0.15% eye drops (extemporaneously manufactured to be stable for a week) are the gold-standard treatment. Here, we aim to develop a sustained-release AmB ocular film to treat FK with an enhanced corneal retention time. As there is a paucity of reliable in vitro models to evaluate ocular drug release and antifungal efficacy under flow, we developed a 3D-printed microfluidic device based on four chambers stacked in parallel, in which lenses previously inoculated with a C. albicans suspension were placed. Under the flow of a physiological fluid over 24 h, the release from the AmB-loaded film that was placed dry onto the surface of the wetted contact lenses was quantified, and their antifungal activity was assessed. AmB sodium deoxycholate micelle (dimeric form) was mixed with sodium alginate and hyaluronic acid (3:1 w/w) and cast into films (0.48 or 2.4%), which showed sustained release over 24 h and resulted in a 1.23-fold reduction and a 5.7-fold reduction in CFU/mL of C. albicans, respectively. This study demonstrates that the sustained delivery of dimeric AmB can be used for the treatment of FK and provides a facile in vitro microfluidic model for the development and testing of ophthalmic antimicrobial therapies.

ORCID iDs

Rapti, Chrysi, Luciano, Francis C., Anaya, Bryan J., Ramirez, Bianca I., Ongoren, Baris, Dea-Ayuela, María Auxiliadora, Lalatsa, Aikaterini ORCID logoORCID: https://orcid.org/0000-0003-4791-7468 and Serrano, Dolores R.;
CORE (COnnecting REpositories)